Quentin Hill: UK Will Have Access to Generic Eltrombopag
Quentin Hill, Honorary Clinical Associate Professor at University of Leeds, shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag. Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licenced treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar and greater use of generic eltrombopag will result in a substantial, multi-million-pound, cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP. However patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
The full published position statement can be found here.
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026